Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: updated efficacy and safety results from VARGADO Cohort C

被引：0
|
作者：
Grohe, C. [1 ]
Wehler, T. [2 ]
Dechow, T. [3 ]
Henschke, S. [4 ]
Schuette, W. [5 ]
Dittrich, I [6 ]
Hammerschmidt, S. [7 ]
Mueller-Huesmann, H. [8 ]
Schumann, C. [9 ]
Krueger, S. [10 ]
Atz, J. [11 ]
Kaiser, R. [11 ]
机构：
[1] Evangel Lung Clin, Dept Pneumol, Berlin, Germany
[2] Evangel Krankenhaus Hamm GmbH, Hamm, Germany
[3] Oncol Haematol Grp Practice, Ravensburg, Germany
[4] Saarland Univ Hosp, Innere Med 5, Med Klin, Homburg, Germany
[5] Krankenhaus Martha Maria Halle Dolau, Halle An Der Saale, Germany
[6] Lungenklin Lostau, Lostau, Germany
[7] Klinikum Chemnitz gGmbH, Dept Internal Med, Chemnitz, Germany
[8] Bruderkrankenhaus St Josef, Klin Hamatol & Onkol, Paderborn, Germany
[9] Klinikverbund Allgau, Clin Pneumol Thorac Oncol Sleep & Resp Med, Kempten, Germany
[10] Florence Nightingale Hosp, Dept Pulmonol Cardiol & Internal Intens Care, Dusseldorf, Germany
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs, Ingelheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V238
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455)
    Grohe, C.
    Gleiber, W.
    Haas, S.
    Mueller-Huesmann, H.
    Schulze, M.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] EFFICACY AND SAFETY OF DOCETAXEL PLUS OXALIPLATIN AS A FIRST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
    Ban, Heejung
    Rang, Hyun-wook
    Kim, Woo-jin
    Park, Chan-woo
    Oh, In-jae
    Rini, Kyu-sik
    Kim, Young-chul
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [43] Efficacy and safety of docetaxel plus oxaliplatin as a first-line chemotherapy in patients with advanced or metastatic non-small cell lung cancer
    Ban, Heejung
    Kim, Kyu-Sik
    Oh, In-Jae
    Yoon, Seong-Hoon
    Lee, Boram
    Yu, Jinyeong
    Kim, Sunmin
    Lee, Ho-Sung
    Shin, Hong-Joon
    Park, Cheol-Kyu
    Kwon, Yong-Soo
    Kim, Yu-Il
    Lim, Sung-Chul
    Kim, Young-Chul
    THORACIC CANCER, 2014, 5 (06) : 525 - 529
  • [44] Efficacy and safety of second-line nab-paclitaxel plus gemcitabine (nab-P plus GEM) after progression on first-line FOLFIRINOX in advanced pancreatic ductal adenocarcinoma (PDAC): Multicenter retrospective analysis
    Yoo, Changhoon
    Jeong, Hyehyun
    Chae, Heejung
    Cheon, Jaekyung
    Chon, Hong Jae
    Ryu, Hyewon
    Kim, Il-Hwan
    Jeong, Jae Ho
    Kim, Kyu-Pyo
    Ryoo, Baek-Yeol
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [45] Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
    Brueckl, Wolfgang M.
    Reck, Martin
    Rittmeyer, Achim
    Kollmeier, Jens
    Wesseler, Claas
    Wiest, Gunther H.
    Christopoulos, Petros
    Stenzinger, Albrecht
    Tufman, Amanda
    Hoffknecht, Petra
    Ulm, Bernhard
    Reich, Fabian
    Ficker, Joachim H.
    Laack, Eckart
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (07) : 3093 - +
  • [46] Anlotinib plus docetaxel versus docetaxel as second-line treatment for advanced non-small cell lung cancer (NSCLC): Updated results from a phase I/II study.
    Fang, Yong
    Pan, Hongming
    Shou, Jiawei
    Hong, Wei
    Guo, Qunyi
    Yang, Xinmei
    Zhu, Dan
    Chen, Jun
    Lu, Liqin
    Rao, Chuangzhou
    Lan, Fen
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Second-line treatment outcomes following first-line chemotherapy plus immunotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC): A multicenter study.
    Pons-Tostivint, Elvire
    Ezzedine, Remy
    Goronflot, Thomas
    Crequit, Perrine
    Chatellier, Thierry
    Raimbourg, Judith
    Bennouna, Jaafar
    Leprieur, Etienne Giroux
    Porte, Marie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
    Noboru Yamamoto
    Hirotsugu Kenmotsu
    Koichi Goto
    Koji Takeda
    Terufumi Kato
    Masayuki Takeda
    Hidehito Horinouchi
    Isao Saito
    Akiko Sarashina
    Tetsuya Tanaka
    Nassim Morsli
    Kazuhiko Nakagawa
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 685 - 694
  • [49] Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO
    Pivot, Xavier
    Schneeweiss, Andreas
    Verma, Shailendra
    Thomssen, Christoph
    Passos-Coelho, Jose Luis
    Benedetti, Giovanni
    Ciruelos, Eva
    von Moos, Roger
    Chang, Hong-Tai
    Duenne, Anja-Alexandra
    Miles, David W.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (16) : 2387 - 2395
  • [50] An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Goto, Koichi
    Takeda, Koji
    Kato, Terufumi
    Takeda, Masayuki
    Horinouchi, Hidehito
    Saito, Isao
    Sarashina, Akiko
    Tanaka, Tetsuya
    Morsli, Nassim
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (04) : 685 - 694
12345